Small molecules that correct defective trafficking of the CFTR chloride channel may be the most well-known success, with drug combinations that simultaneously improve the delivery of CFTR to the plasma membrane and potentiate channel opening in routine clinical use for cystic fibrosis [45,46]. The gene discussed is CFTR; the disease is cystic fibrosis.